Steven E. Cagas
University of Medicine and Dentistry of New Jersey
6 Papers
Steven E. Cagas is an academic researcher from University of Medicine and Dentistry of New Jersey. The author has contributed to research in topics: Proteome & Proteomics. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Profiling the Aspergillus fumigatus Proteome in Response to Caspofungin
TL;DR: The proteomic response of Aspergillus fumigatus to caspofungin was evaluated by gel-free isobaric tagging for relative and absolute quantitation (iTRAQ) as a means to determine potential biomarkers of drug action to identify biomarkers that assess the relative efficacy of echinocandin drug therapy.
The proteomic signature of Aspergillus fumigatus during early development
TL;DR: This study provides insights into early pathways activated during growth and development of A. fumigatus, revealing a pathogen that is gearing up for rapid growth by building translation machinery, generating ATP, and is very much committed to aerobic metabolism.
40
Profiling the Aspergillus fumigatus Proteome in Response to Caspofungin
Steven E. Cagas,Mohit Jain,Hong Li,David S. Perlin +3 more
TL;DR: The proteomic response of Aspergillus fumigatus to caspofungin was evaluated by gel-free isobaric tagging for relative and absolute quantitation (iTRAQ) as a means to determine potential biomarkers of drug action to identify biomarkers that assess the relative efficacy of echinocandin drug therapy.
5
Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5–11 Years of Age: A Post Hoc Analysis of a Phase 3 Study
Jeffery Baker,Stan L. Block,Steven E. Cagas,Laura Burleigh Macutkiewicz,Colleen Collins,M. Sadeghi,Suman De Sarkar,Sarah R. Williams +7 more
TL;DR: Safety, efficacy and virological results in children 5–11 years were similar to those from the overall study population 1–<12 years of age, and single-dose baloxavir provides an additional treatment option for pediatric patients 5-11 years old with influenza.